Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

The Lancet Oncology

Volumn 9, Issue 10, 2008, Pages 962-972

  Linardou, Helena ^a   Dahabreh, Issa J ^b   Kanaloupiti, Dimitra ^a   Siannis, Fotios ^d,e   Bafaloukos, Dimitrios ^a   Kosmidis, Paris ^f   Papadimitriou, Christos A ^c   Murray, Samuel ^a  

^a METROPOLITAN HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Alexandras Hospital   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e MRC BIOSTATISTICS UNIT   (United Kingdom)

^f HYGEIA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; PUBLICATION; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENES, RAS; GENETIC MARKERS; HUMANS; LIKELIHOOD FUNCTIONS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 52749099497     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70206-7     Document Type: Article

References (90)

1. Herbst R.S., Fukuoka M., and Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 4 (2004) 956-965
2. Normanno N., De Luca A., Bianco C., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366 (2006) 2-16
3. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 (2001) S9-S15
4. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., and Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284 (2003) 31-53
5. Mendelshon J., and Baselga J. Epidermal growth factor targeting in cancer. Semin Oncol 33 (2006) 369-385
6. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
7. Ciadiello F., and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358 (2008) 1160-1174
8. Rocha-Lima C.M., Soares H.P., Raez L.E., and Singal R. EGFR targeting of solid tumors. Cancer Control 14 (2007) 295-304
9. Zhang W., Gordon M., and Lenz H.J. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 38 (2006) 545-551
10. Moosmann N., and Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther 7 (2007) 243-256
11. Rivera F., Vega-Villegas M.E., Lopez-Brea M.F., and Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutuzumab. Acta Oncologica 47 (2008) 9-19
12. Albanell J., and Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets 6 (2005) 259-274
13. Dassonville O., Bozec A., Fischel J.L., and Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 62 (2007) 53-61
14. Hirsch F.R., and Bunn P.A. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?. J Clin Oncol 23 (2005) 9044-9047
15. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
16. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
17. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
18. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
19. Murray S., Dahabreh I., Linardou E., Manoloukos M., Bafaloukos D., and Kosmidis P. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and TKI efficacy in NSCLC: an analytical database. J Thor Oncol 3 (2008) 832-839
20. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
21. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2 (2004) 1497-1500
22. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 2556-2568
23. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) 57-61
24. Endoh H., Yatabe Y., Kosaka K., Kuwano H., and Mitsudomi T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 1 (2006) 629-634
25. Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
26. Zucali P.A., Ruiz M.G., Giovannetti E., et al. Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 19 (2008) 1605-1612
27. Giaccone G., Ruiz M.G., Le Chevalier T., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12 (2006) 6049-6055
28. Cappuzzo F., Ligorio C., Janne P.A., et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phosphor-Akt-positive or never smoker patients with advanced non-small cell lung cancer: the ONCOBELL trial. J Clin Oncol 25 (2007) 2248-2255
29. Ichihara S., Toyooka S., Fujiwara Y., et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small cell lung cancer. Int J Cancer 120 (2007) 1239-1247
30. Loprevite M., Tiseo M., Chiaramondia M., et al. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non-small cell lung cancer. Clin Cancer Res 13 (2007) 6518-6526
31. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
32. Chang J.W., Liu H.P., Hsieh M.H., et al. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Lung Cancer 61 (2008) 328-339
33. Han S.W., Kim T.Y., Jeon Y.K., et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12 (2006) 2538-2544
34. van Zandwijk N., Mathy A., Boerrigter L., et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small cell lung cancer. Ann Oncol 18 (2007) 99-103
35. Hirsch F.R., Varella-Garcia M., Cappuzzo F., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small cell lung cancer patients treated with gefitinib. Ann Oncol 18 (2007) 752-760
36. Jackman D.M., Yeap B.Y., Lindeman N.I., et al. Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small cell lung cancer. J Clin Oncol 25 (2007) 760-766
37. Miller V.A., Riely G.J., Zakowski M.F., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26 (2008) 1472-1478
38. Massarelli E., Varella-Garcia M., Tang X., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 13 (2007) 2890-2896
39. Sasaki H., Endo K., Okuda K., et al. Epidermal growth factor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol 134 (2008) 569-577
40. Ramalingam S., Forster J., Naret C., et al. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol 3 (2008) 258-264
41. Yamanaka S., Gu Z., Sato M., et al. siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology 75 (2008) 2-8
42. Bell D.W., Lynch T.J., Haserlat S.M., et al. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 (2005) 8081-8092
43. Fujimoto N., Wislez M., Zhang J., et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65 (2005) 11478-11485
44. Liu F., Jiang B., Gong S.J., et al. Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer. Chin J Med Genet 24 (2007) 31-34
45. Sasaki H., Endo K., Mizuno K., et al. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer 51 (2006) 135-136
46. Tomizawa Y., Iijma H., Sunaga N., et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 6816-6822
47. Kondo M., Yokoyama T., Fukui T., et al. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 50 (2005) 385-391
48. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
49. Kosaka T., Yatabe Y., Endoh H., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12 (2006) 5764-5769
50. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
51. Andreyev H.J., Norman A.R., Cunnigham D., et al. Kristen ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85 (2001) 692-696
52. Bardelli A., and Velculescu V.E. Mutational analysis of gene families in human cancer. Curr On Genet Dev 15 (2005) 5-12
53. Baselga J., and Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 26 (2008) 1-3
54. Adams R., and Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev Anticancer Ther 7 (2007) 503-518
55. Giusti R.M., Shastri K.A., Cohen M.H., Keegan P., and Pazdur R. FDA drug approval summary: Panitumumab (Vectibix™). Oncologist 12 (2007) 577-583
56. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 1626-1634
57. Frattini M., Saletti P., Romagnani E., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97 (2007) 1139-1145
58. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19 (2008) 508-515
59. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96 (2007) 1166-1169
60. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286
61. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 (2007) 2643-2648
62. Khambata-Ford S., Garrett C.R., Metropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25 (2007) 3230-3237
63. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 (2008) 374-379
64. Lievre A., Bachet J.B., Corre D.L., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
65. Reitsma J.B., Glas A.S., Rutjes A., Scholten R.J.P.M., Bossuyt P.M., and Zwinderman A.H. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epid 58 (2005) 982-990
66. Deeks J.J. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 323 (2001) 157-162
67. Deeks J.J., and Altman D.G. Diagnostic tests 4: likelihood ratios. BMJ 329 (2004) 168-169
68. Oldenhuis C.N., Oosting S.F., Gietema J.A., and de Vries E.G. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44 (2008) 946-953
69. Gasparini G., Pozza F., and Harris A.L. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85 (1993) 1206-1219
70. Biomarkers definitions working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
71. Harbord R.M. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 8 (2007) 239-251
72. Whiting P.F., Sterne J.C., Westwood M.E., et al. Graphical presentation of diagnostic information. BMC Med Res Methodol 8 (2008) 20
73. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
74. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000) 2008-2012
75. Chou L.S., Garey J., Oishi K., and Kim E. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer 8 (2006) S15-S22
76. Chouaid C., Monnet I., Robinet G., Perol M., Fournel P., and Vergnenegre A. Economic impact of gefitinib for refractory non-small cell lung cancer: a Markov model-based analysis. Curr Med Res Opin 23 (2007) 1509-1515
77. Krol M., Koopman M., Uyl-de Groot C., and Punt C.J. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin Pharmacother 8 (2007) 1313-1328
78. Norum J. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. J Chemother 18 (2006) 532-537
79. Shepherd F.A. Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. J Clin Oncol 26 (2008) 2426-2427
80. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 25 (2007) 1760-1764
81. Van Custem E., Lang I., D'haens G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Proc Am Soc Clin Oncol 26 suppl (2008) abstr 2.
82. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. Proc Am Soc Clin Oncol 26 suppl (2008) abstr 4000.
83. Rajagopalan H., Bardelli A., Lengaur C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
84. Trivella M., Pezzella F., Pastorino U., Harris A.L., Altman D.G., and Prognosis in Lung Cancer (PILC) Collaborative Study Group. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 8 (2007) 488-499
85. Johnson K.R., Ringland C., Stokes B.J., et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 7 (2006) 741-746
86. Lara Jr. P.N., Redman M.W., Kelly K., et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomised trials. J Clin Oncol 26 (2008) 463-467
87. Buyse M., Thirion P., Carlson R.W., Burzykowski T., Molenberghs G., and Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356 (2000) 373-378
88. Moore M.J., Goldstein D., and Hamm J. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25 (2007) 1960-1966
89. Moore M.J. The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. Proc Am Soc Clin Oncol 25 suppl (2007) abstr 4521.
90. Hayes D.F., Bast R.C., Desch C.E., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88 (1996) 1456-1466